Excitotoxic and oxidative cross-talk between motor neurons and glia in ALS pathogenesis

Trends in Neurosciences

Volumn 27, Issue 1, 2004, Pages 17-23

  Rao, Shyam D ^a   Weiss, John H ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTAMIC ACID; REACTIVE OXYGEN METABOLITE;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL; ASTROCYTE; BIOLOGICAL MODEL; CELL COMMUNICATION; CELL CYCLE; CENTRAL NERVOUS SYSTEM; GLIA; HUMAN; METABOLISM; MOTONEURON; MOTOR CORTEX; NONHUMAN; OXIDATION; PATHOGENESIS; PATHOLOGY; PHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SPINAL CORD; STRESS;

EID: 0346156083     PISSN: 01662236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tins.2003.11.001     Document Type: Article

References (71)

1. Rowland L.P., Shneider N.A. Amyotrophic lateral sclerosis. N. Engl. J. Med. 344:2001;1688-1700.
2. Menzies F.M., et al. Mitochondrial involvement in amyotrophic lateral sclerosis. Neurochem. Int. 40:2002;543-551.
3. Robberecht W. Oxidative stress in amyotrophic lateral sclerosis. J. Neurol. 247:(Suppl. 1):2000;I1-I6.
4. Tu P.H., et al. Transgenic mice carrying a human mutant superoxide dismutase transgene develop neuronal cytoskeletal pathology resembling human amyotrophic lateral sclerosis lesions. Proc. Natl. Acad. Sci. U. S. A. 93:1996;3155-3160.
5. Rothstein J.D. Excitotoxicity hypothesis. Neurology. 47:(Suppl. 2):1996;S19-S25.
6. Appel S.H., Simpson E.P. Activated microglia: the silent executioner in neurodegenerative disease? Curr. Neurol. Neurosci. Rep. 1:2001;303-305.
7. Anderson C.M., Swanson R.A. Astrocyte glutamate transport: review of properties, regulation, and physiological functions. Glia. 32:2000;1-14.
8. Choi D.W. Glutamate neurotoxicity and diseases of the nervous system. Neuron. 1:1988;623-634.
9. Plaitakis A., Caroscio J.T. Abnormal glutamate metabolism in amyotrophic lateral sclerosis. Ann. Neurol. 22:1987;575-579.
10. Rothstein J.D., et al. Excitatory amino acids in amyotrophic lateral sclerosis: an update. Ann. Neurol. 30:1991;224-225.
11. Shaw P.J., et al. CSF and plasma amino acid levels in motor neuron disease: elevation of CSF glutamate in a subset of patients. Neurodegeneration. 4:1995;209-216.
12. Spreux-Varoquaux O., et al. Glutamate levels in cerebrospinal fluid in amyotrophic lateral sclerosis: a reappraisal using a new HPLC method with coulometric detection in a large cohort of patients. J. Neurol. Sci. 193:2002;73-78.
13. Rothstein J.D., et al. Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis. N. Engl. J. Med. 326:1992;1464-1468.
14. Rothstein J.D., et al. Chronic inhibition of glutamate uptake produces a model of slow neurotoxicity. Proc. Natl. Acad. Sci. U. S. A. 90:1993;6591-6595.
15. Carriedo S.G., et al. Motor neurons are selectively vulnerable to AMPA/kainate receptor-mediated injury in vitro. J. Neurosci. 16:1996;4069-4079.
16. Bensimon G., et al. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N. Engl. J. Med. 330:1994;585-591.
17. 2+ permeable AMPA or kainate receptors: possible key factors in selective neurodegeneration. Trends Neurosci. 23:2000;365-371.
18. Hugon J., et al. Kainic acid induces early and delayed degenerative neuronal changes in rat spinal cord. Neurosci. Lett. 104:1989;258-262.
19. 2+ dependent. NeuroReport. 6:1995;945-948.
20. Ikonomidou C., et al. Motor neuron degeneration induced by excitotoxin agonists has features in common with those seen in the SOD-1 transgenic mouse model of amyotrophic lateral sclerosis. J. Neuropathol. Exp. Neurol. 55:1996;211-224.
21. Mennini T., et al. Biochemical and pharmacological evidence of a functional role of AMPA receptors in motor neuron dysfunction in mnd mice. Eur. J. Neurosci. 11:1999;1705-1710.
22. Canton T., et al. RPR 119990, a novel α-amino-3-hydroxy-5-methyl-4- isoxazolepropionic acid antagonist: synthesis, pharmacological properties, and activity in an animal model of amyotrophic lateral sclerosis. J. Pharmacol. Exp. Ther. 299:2001;314-322.
23. Van Damme P., et al. The AMPA receptor antagonist NBQX prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis. Neurosci. Lett. 343:2003;81-84.
24. Williams T.L., et al. Calcium-permeable α-amino-3-hydroxy-5-methyl- 4-isoxazole propionic acid receptors: a molecular determinant of selective vulnerability in amyotrophic lateral sclerosis. Ann. Neurol. 42:1997;200-207.
25. Vandenberghe W., et al. AMPA receptor calcium permeability, GluR2 expression, and selective motoneuron vulnerability. J. Neurosci. 20:2000;123-132.
26. Van Damme P., et al. GluR2-dependent properties of AMPA receptors determine the selective vulnerability of motor neurons to excitotoxicity. J. Neurophysiol. 88:2002;1279-1287.
27. 2+ permeability of KA-AMPA-gated glutamate receptor channels depends on subunit composition. Science. 252:1991;851-853.
28. Alexianu M.E., et al. The role of calcium-binding proteins in selective motoneuron vulnerability in amyotrophic lateral sclerosis. Ann. Neurol. 36:1994;846-858.
29. Elliott J.L., Snider W.D. Parvalbumin is a marker of ALS-resistant motor neurons. NeuroReport. 6:1995;449-452.
30. Beers D.R., et al. Parvalbumin overexpression alters immune-mediated increases in intracellular calcium, and delays disease onset in a transgenic model of familial amyotrophic lateral sclerosis. J. Neurochem. 79:2001;499-509.
31. Van Den Bosch L., et al. Protective effect of parvalbumin on excitotoxic motor neuron death. Exp. Neurol. 174:2002;150-161.
32. Vanselow B.K., Keller B.U. Calcium dynamics and buffering in oculomotor neurones from mouse that are particularly resistant during amyotrophic lateral sclerosis (ALS)-related motoneurone disease. J. Physiol. 525:2000;433-445.
33. 2+ overload and ROS generation in spinal motor neurons in vitro. J. Neurosci. 20:2000;240-250.
34. Rothstein J.D., et al. Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Ann. Neurol. 38:1995;73-84.
35. Trotti D., et al. SOD1 mutants linked to amyotrophic lateral sclerosis selectively inactivate a glial glutamate transporter. Nat. Neurosci. 2:1999;427-433.
36. Tanaka K., et al. Epilepsy and exacerbation of brain injury in mice lacking the glutamate transporter GLT-1. Science. 276:1997;1699-1702.
37. Bruijn L.I., et al. ALS-linked SOD1 mutant G85R mediates damage to astrocytes and promotes rapidly progressive disease with SOD1-containing inclusions. Neuron. 18:1997;327-338.
38. Bristol L.A., Rothstein J.D. Glutamate transporter gene expression in amyotrophic lateral sclerosis motor cortex. Ann. Neurol. 39:1996;676-679.
39. Lin C.L., et al. Aberrant RNA processing in a neurodegenerative disease: the cause for absent EAAT2, a glutamate transporter, in amyotrophic lateral sclerosis. Neuron. 20:1998;589-602.
40. Nagai M., et al. Identification of alternative splicing forms of GLT-1 mRNA in the spinal cord of amyotrophic lateral sclerosis patients. Neurosci. Lett. 244:1998;165-168.
41. Meyer T., et al. The RNA of the glutamate transporter EAAT2 is variably spliced in amyotrophic lateral sclerosis and normal individuals. J. Neurol. Sci. 170:1999;45-50.
42. Gegelashvili G., et al. Neuronal soluble factors differentially regulate the expression of the GLT1 and GLAST glutamate transporters in cultured astroglia. J. Neurochem. 69:1997;2612-2615.
43. Robinson M.B. Regulated trafficking of neurotransmitter transporters: common notes but different melodies. J. Neurochem. 80:2002;1-11.
44. Volterra A., et al. Glutamate uptake inhibition by oxygen free radicals in rat cortical astrocytes. J. Neurosci. 14:1994;2924-2932.
45. Trotti D., et al. Glutamate transporters are oxidant-vulnerable: a molecular link between oxidative and excitotoxic neurodegeneration? Trends Pharmacol. Sci. 19:1998;328-334.
46. Pedersen W.A., et al. Protein modification by the lipid peroxidation product 4-hydroxynonenal in the spinal cords of amyotrophic lateral sclerosis patients. Ann. Neurol. 44:1998;819-824.
47. Deitch J.S., et al. GLT-1 glutamate transporter levels are unchanged in mice expressing G93A human mutant SOD1. J. Neurol. Sci. 193:2002;117-126.
48. Trotti D., et al. Neuronal and glial glutamate transporters possess an SH-based redox regulatory mechanism. Eur. J. Neurosci. 9:1997;1236-1243.
49. Drachman D.B., et al. Cyclooxygenase 2 inhibition protects motor neurons and prolongs survival in a transgenic mouse model of ALS. Ann. Neurol. 52:2002;771-778.
50. Pompl P.N., et al. A therapeutic role for cyclooxygenase-2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis. FASEB J. 17:2003;725-727.
51. McGeer P.L., McGeer E.G. Inflammatory processes in amyotrophic lateral sclerosis. Muscle Nerve. 26:2002;459-470.
52. Bush A.I. Is ALS caused by an altered oxidative activity of mutant superoxide dismutase? Nat. Neurosci. 5:2002;919.
53. Valentine J.S., Hart P.J. Misfolded CuZnSOD and amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. U. S. A. 100:2003;3617-3622.
54. Rao S.D., et al. Disruption of glial glutamate transport by reactive oxygen species produced in motor neurons. J. Neurosci. 23:2003;2627-2633.
55. Sasaki S., et al. Excitatory amino acid transporter 1 and 2 immunoreactivity in the spinal cord in amyotrophic lateral sclerosis. Acta Neuropathol. (Berl.). 100:2000;138-144.
56. Abe K., et al. Induction of nitrotyrosine-like immunoreactivity in the lower motor neuron of amyotrophic lateral sclerosis. Neurosci. Lett. 199:1995;152-154.
57. Ferrante R.J., et al. Increased 3-nitrotyrosine and oxidative damage in mice with a human copper/zinc superoxide dismutase mutation. Ann. Neurol. 42:1997;326-334.
58. Guegan C., et al. Recruitment of the mitochondrial-dependent apoptotic pathway in amyotrophic lateral sclerosis. J. Neurosci. 21:2001;6569-6576.
59. Gelinas S., et al. Effect of oxidative stress on stability and structure of neurofilament proteins. Biochem. Cell Biol. 78:2000;667-674.
60. Rakhit R., et al. Oxidation-induced misfolding and aggregation of superoxide dismutase and its implications for amyotrophic lateral sclerosis. J. Biol. Chem. 277:2002;47551-47556.
61. Brooks B.R. Natural history of ALS: symptoms, strength, pulmonary function, and disability. Neurology. 47:(Suppl. 2):1996;S71-S81.
62. Gong Y.H., et al. Restricted expression of G86R Cu/Zn superoxide dismutase in astrocytes results in astrocytosis but does not cause motoneuron degeneration. J. Neurosci. 20:2000;660-665.
63. Pramatarova A., et al. Neuron-specific expression of mutant superoxide dismutase 1 in transgenic mice does not lead to motor impairment. J. Neurosci. 21:2001;3369-3374.
64. Lino M.M., et al. Accumulation of SOD1 mutants in postnatal motoneurons does not cause motoneuron pathology or motoneuron disease. J. Neurosci. 22:2002;4825-4832.
65. Clement A.M., et al. Wild-type nonneuronal cells extend survival of SOD1 mutant motor neurons in ALS mice. Science. 302:2003;113-117.
66. Zhang W., et al. Additive neuroprotective effects of minocycline with creatine in a mouse model of ALS. Ann. Neurol. 53:2003;267-270.
67. Kriz J., et al. Efficient three-drug cocktail for disease induced by mutant superoxide dismutase. Ann. Neurol. 53:2003;429-436.
68. Kruman I.I., et al. ALS-linked Cu/Zn-SOD mutation increases vulnerability of motor neurons to excitotoxicity by a mechanism involving increased oxidative stress and perturbed calcium homeostasis. Exp. Neurol. 160:1999;28-39.
69. Ghadge G.D., et al. Glutamate carboxypeptidase II inhibition protects motor neurons from death in familial amyotrophic lateral sclerosis models. Proc. Natl. Acad. Sci. U. S. A. 100:2003;9554-9559.
70. Spencer P.S., et al. Guam amyotrophic lateral sclerosis-parkinsonism- dementia linked to a plant excitant neurotoxin. Science. 237:1987;517-522.
71. Banack S.A., Cox P.A. Biomagnification of cycad neurotoxins in flying foxes: Implications for ALS-PDC in Guam. Neurology. 61:2003;387-389.